secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001104659-24-101816
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039
--------------------------------------------------------------------------------

- Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.
- Qilu granted royalty-free license to market generic revfenacin on or after April 23, 2039.
- Settlement subject to review by U.S. DOJ and FTC as required by law.
- Patent litigation against three other ANDA filers (Cipla, Eugia, Mankind) remains pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924101816/0001104659-24-101816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924101816/tm2424315d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-101816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer